Johnson & Johnson announced plans to resume shipments of its coronavirus vaccine in Europe following a review by the European Medicines Agency. The EMA found that unusual blood clots should be listed as a “very rare” side effect of the vaccine and that the overall benefits outweigh the risks.
The New Paper
This story is from the April 21, 2021 edition of The New Paper. To receive TNP daily subscribe below.
By subscribing, you agree to our Terms of Service & Privacy Policy.
